Loss narrows sequentially. Boundless Bio Inc reported a loss of $0.58 per share for Q4 2025, narrower than the $0.62 loss in Q3 2025 and the $0.74 loss a year ago. The biotech posted a net loss of $12.9 million on an operating loss of $14 million. The 21.6% year-over-year improvement in per-share losses reflects the company’s progression through clinical development stages, though the stock traded flat at $1.12 on volume of 51,393 shares.
Revenue materializes for the first time. The company recorded $17.3 million in revenue for Q4 2025, a sharp departure from zero revenue in both the prior quarter and the year-ago period. This marks the first meaningful commercial activity in the company’s reported history. Management issued full-year 2026 revenue guidance of $78 million to $80 million, signaling expectations for sustained revenue generation as the biotech transitions from pure clinical-stage operations.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share first appeared on test.
